Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 130

1.

Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.

Raj K, Eikema DJ, McLornan DP, Olavarria E, Blok HJ, Bregante S, Ciceri F, Passweg J, Ljungman P, Schaap N, Carlson K, Zuckerman T, de Wreede LC, Volin L, Koc Y, Diez-Martin JL, Brossart P, Wolf D, Blaise D, Bartolomeo PD, Vitek A, Robin M, Yakoub-Agha I, Chalandon Y, Kroger N.

Biol Blood Marrow Transplant. 2018 Nov 5. pii: S1083-8791(18)30650-5. doi: 10.1016/j.bbmt.2018.10.017. [Epub ahead of print]

PMID:
30408564
2.

Allogeneic stem cell transplantation from unrelated donors in acute leukaemia.

Lozano Cerrada S, Altaf SY, Olavarria E.

Curr Opin Oncol. 2018 Nov;30(6):418-424. doi: 10.1097/CCO.0000000000000485.

PMID:
30222641
3.

Lineage switch from acute myeloid leukemia to T cell/myeloid mixed phenotype acute leukemia: First report of an adult case.

Hanley BP, Yebra-Fernandez E, Palanicawandar R, Olavarria E, Naresh KN.

Am J Hematol. 2018 Dec;93(12):E395-E397. doi: 10.1002/ajh.25283. Epub 2018 Oct 2. No abstract available.

PMID:
30203419
4.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15407. [Epub ahead of print]

5.

Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J.

Clin Nutr. 2018 Mar 28. pii: S0261-5614(18)30120-1. doi: 10.1016/j.clnu.2018.03.008. [Epub ahead of print]

PMID:
29650256
6.

Correction to: An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188. doi: 10.1007/s00432-017-2532-1.

7.

Functional specific-T-cell expansion after first cytomegalovirus reactivation predicts viremia control in allogeneic hematopoietic stem cell transplant recipients.

Ciáurriz M, Beloki L, Zabalza A, Bandrés E, Mansilla C, Pérez-Valderrama E, Lachén M, Rodríguez-Calvillo M, Ramírez N, Olavarría E.

Transpl Infect Dis. 2017 Dec;19(6). doi: 10.1111/tid.12778. Epub 2017 Oct 25.

PMID:
28921749
8.

First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY.

Goldberg SL, Cortes JE, Gambacorti-Passerini C, Hehlmann R, Khoury HJ, Michallet M, Paquette RL, Simonsson B, Zyczynski T, Foreman A, Abruzzese E, Andorsky D, Beeker A, Cony-Makhoul P, Hansen R, Lomaia E, Olavarria E, Mauro MJ.

Am J Hematol. 2017 Nov;92(11):1214-1223. doi: 10.1002/ajh.24887. Epub 2017 Sep 25.

9.

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.

Pavlů J, Auner HW, Szydlo RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM.

Bone Marrow Transplant. 2017 Dec;52(12):1599-1601. doi: 10.1038/bmt.2017.113. Epub 2017 Jun 26.

10.

Immunosuppression-associated Kaposi sarcoma following stem cell transplantation.

Innes AJ, Lee M, Francis N, Olavarria E.

Br J Haematol. 2017 Jul;178(1):9. doi: 10.1111/bjh.14659. Epub 2017 Jun 7. No abstract available.

11.

An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phase.

Steegmann JL, Colomer D, Gómez-Casares MT, García-Gutiérrez V, Ortí G, Ramírez-Payer A, Olavarria E, Vall-Llovera F, Giraldo P, Conde E, Vallansot R, López-Lorenzo JL, Palomera L, Álvarez-Larrán A, Conesa V, Bautista G, Casas L, Giles F, Hochhaus A, Casado-Montero LF.

J Cancer Res Clin Oncol. 2017 Oct;143(10):2059-2066. doi: 10.1007/s00432-017-2445-z. Epub 2017 May 27. Erratum in: J Cancer Res Clin Oncol. 2018 Jan;144(1):187-188.

12.

Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.

Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.

Cancer. 2017 Aug 1;123(15):2875-2880. doi: 10.1002/cncr.30558. Epub 2017 Apr 7.

13.

Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2017 Jun;177(5):759-765. doi: 10.1111/bjh.14619. Epub 2017 Mar 28.

PMID:
28369779
14.

BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation.

Pello OM, Innes AJ, Bradshaw A, Finn SA, Uddin S, Bray E, Olavarria E, Apperley JF, Pavlů J.

Eur J Haematol. 2017 Jun;98(6):632-634. doi: 10.1111/ejh.12848. Epub 2017 Mar 1.

15.

Pathology findings in patients with cutaneous T-cell lymphomas treated with allogeneic haematopoietic stem cell transplantation.

Menter T, Medani H, Olavarria E, Kanfer E, Naresh KN.

Br J Haematol. 2018 Mar;180(6):904-908. doi: 10.1111/bjh.14479. Epub 2016 Dec 16. No abstract available.

PMID:
27984647
16.

C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality.

Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J.

Br J Haematol. 2018 Mar;180(6):889-892. doi: 10.1111/bjh.14454. Epub 2016 Nov 29. No abstract available.

17.

Matched unrelated donor transplants-State of the art in the 21st century.

Altaf SY, Apperley JF, Olavarria E.

Semin Hematol. 2016 Oct;53(4):221-229. doi: 10.1053/j.seminhematol.2016.07.002. Epub 2016 Jul 25. Review.

18.

Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program.

Corbacioglu S, Carreras E, Mohty M, Pagliuca A, Boelens JJ, Damaj G, Iacobelli M, Niederwieser D, Olavarría E, Suarez F, Ruutu T, Verdonck L, Hume R, Nejadnik B, Lai C, Finetto G, Richardson P.

Biol Blood Marrow Transplant. 2016 Oct;22(10):1874-1882. doi: 10.1016/j.bbmt.2016.07.001. Epub 2016 Jul 7.

19.

Outcome of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic stem cell transplantation in the era of targeted therapy. A report from the EBMT Chronic Malignancies Working Party.

Koenecke C, Heim D, van Biezen A, Heuser M, Aljurf M, Kyrcz-Krzemien S, Volin L, de Souza CA, Gedde-Dahl T, Sengeloev H, Schanz U, Komarnicki M, Arroyo CH, Tholouli E, Gluckman E, Esquirol A, Yakoub-Agha I, Gürman G, Olavarria E, Kröger N.

Bone Marrow Transplant. 2016 Sep;51(9):1259-61. doi: 10.1038/bmt.2016.97. Epub 2016 Apr 25. No abstract available.

PMID:
27111041
20.

Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study.

Gratwohl A, Iacobelli S, Bootsman N, van Biezen A, Baldomero H, Arcese W, Arnold R, Bron D, Cordonnier C, Ernst P, Ferrant A, Frassoni F, Gahrton G, Richard C, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schattenberg A, Schmitz N, Torres-Gomez A, Zwaan F, Apperley J, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation EBMT.

Ann Hematol. 2016 May;95(6):967-72. doi: 10.1007/s00277-016-2638-6. Epub 2016 Mar 19.

PMID:
26994010
21.

Streptamer technology allows accurate and specific detection of CMV-specific HLA-A*02 CD8+ T cells by flow cytometry.

Ciáurriz M, Beloki L, Bandrés E, Mansilla C, Zabalza A, Pérez-Valderrama E, Lachén M, Ibáñez B, Olavarría E, Ramírez N.

Cytometry B Clin Cytom. 2017 Mar;92(2):153-160. doi: 10.1002/cyto.b.21367. Epub 2016 Apr 4.

22.

Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.

Kaplan A, Lindgren B, Marschner S, Aznar M, Zalba S, Sánchez P, Ayape ML, Olavarría E, Antelo ML.

Transfus Apher Sci. 2016 Apr;54(2):248-52. doi: 10.1016/j.transci.2015.08.004. Epub 2015 Aug 28.

PMID:
26345109
23.

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, Rambaldi A, Mesa R, Tefferi A, Griesshammer M, Gupta V, Harrison C, Alchalby H, Vannucchi AM, Cervantes F, Robin M, Ditschkowski M, Fauble V, McLornan D, Ballen K, Popat UR, Passamonti F, Rondelli D, Barosi G.

Leukemia. 2015 Nov;29(11):2126-33. doi: 10.1038/leu.2015.233. Epub 2015 Aug 21. Review.

PMID:
26293647
24.

The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Ciáurriz M, Zabalza A, Beloki L, Mansilla C, Pérez-Valderrama E, Lachén M, Bandrés E, Olavarría E, Ramírez N.

Cell Mol Life Sci. 2015 Nov;72(21):4049-62. doi: 10.1007/s00018-015-1986-z. Epub 2015 Jul 15. Review.

PMID:
26174234
25.

Antifungal prophylaxis with anidulafungin to minimize drug interactions with an antiepileptic treatment in a hematopoietic stem cell transplant recipient.

Feliu J, Del Pozo JL, Azanza JR, García-Muñoz R, Zabalza A, Gorosquieta A, Pérez-Equiza E, Olavarría E.

J Clin Pharm Ther. 2015 Oct;40(5):601-603. doi: 10.1111/jcpt.12299. Epub 2015 Jun 13.

PMID:
26073924
26.

Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).

Antelo ML, Zabalza A, Sánchez Antón MP, Zalba S, Aznar M, Mansilla C, Ramírez N, Olavarría E.

J Clin Apher. 2016 Feb;31(1):48-52. doi: 10.1002/jca.21401. Epub 2015 May 23.

PMID:
26011178
27.

Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood.

Beloki L, Ciaurriz M, Mansilla C, Zabalza A, Perez-Valderrama E, Samuel ER, Lowdell MW, Ramirez N, Olavarria E.

J Transl Med. 2015 May 20;13:165. doi: 10.1186/s12967-015-0515-z.

28.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19.

29.

CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers.

Beloki L, Ciaurriz M, Mansilla C, Zabalza A, Perez-Valderrama E, Samuel ER, Lowdell MW, Ramirez N, Olavarria E.

J Transl Med. 2014 Nov 19;12:317. doi: 10.1186/s12967-014-0317-8.

30.

Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.

Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, Poiré X, Kobbe G, Narni F, Cortelezzi A, Olavarría E, Schmitz N, Sureda A, Dreger P.

J Clin Oncol. 2014 Oct 10;32(29):3347-8. doi: 10.1200/JCO.2014.57.5597. Epub 2014 Aug 25. No abstract available.

PMID:
25154828
31.

Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT.

Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NP, Finke J, Robin M, Fedele R, Bron D, Yakoub-Agha I, van Biezen A, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Haematologica. 2014 Sep;99(9):1492-8. doi: 10.3324/haematol.2013.100198. Epub 2014 Jul 4.

32.

Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.

Beloki L, Ramírez N, Olavarría E, Samuel ER, Lowdell MW.

Cytotherapy. 2014 Oct;16(10):1390-408. doi: 10.1016/j.jcyt.2014.05.009. Epub 2014 Jun 18.

PMID:
24954783
33.

Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.

Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C, Olavarría E, Andreu E, Prósper F, Díez-Campelo M, Regidor C, Villaron E, López-Corral L, Caballero D, Cañizo MC, Pérez-Simon JA.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1580-5. doi: 10.1016/j.bbmt.2014.06.015. Epub 2014 Jun 19.

34.

Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.

Robin M, Giannotti F, Deconinck E, Mohty M, Michallet M, Sanz G, Chevallier P, Cahn JY, Legrand F, Rovira M, Passweg J, Sierra J, Nguyen S, Maillard N, Yakoub-Agha I, Linkesch W, Cannell P, Marcatti M, Bay JO, Chalandon Y, Kröger N, Gluckman E, Rocha V, Olavarria E, Ruggeri A; Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT).

Biol Blood Marrow Transplant. 2014 Nov;20(11):1841-6. doi: 10.1016/j.bbmt.2014.06.011. Epub 2014 Jun 16.

35.

Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Lussana F, Rambaldi A, Finazzi MC, van Biezen A, Scholten M, Oldani E, Carobbio A, Iacobelli S, Finke J, Nagler A, Volin L, Lamy T, Arnold R, Mohty M, Michallet M, de Witte T, Olavarria E, Kröger N.

Haematologica. 2014 May;99(5):916-21. doi: 10.3324/haematol.2013.094284. Epub 2014 Jan 3.

36.

Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation.

Alchalby H, Zabelina T, Stübig T, van Biezen A, Bornhäuser M, Di Bartolomeo P, Beelen D, Cahn JY, Dreger P, Schroyens W, de Witte T, Olavarria E, Kröger N; Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2014 Feb;20(2):279-81. doi: 10.1016/j.bbmt.2013.10.027. Epub 2013 Nov 4.

37.

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W.

Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97. doi: 10.1016/j.bbmt.2013.10.018. Epub 2013 Oct 23.

38.

Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.

Hirji I, Gupta S, Goren A, Chirovsky DR, Moadel AB, Olavarria E, Victor TW, Davis CC.

Health Qual Life Outcomes. 2013 Oct 8;11:167. doi: 10.1186/1477-7525-11-167.

39.

Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Ramírez N, Beloki L, Ciaúrriz M, Rodríguez-Calvillo M, Escors D, Mansilla C, Bandrés E, Olavarría E.

Cell Mol Life Sci. 2014 Apr;71(7):1211-24.

PMID:
24077876
40.

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI.

Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W.

Blood. 2013 Dec 5;122(24):3863-70. doi: 10.1182/blood-2013-07-514448. Epub 2013 Sep 24.

41.

The abrogation of TCR-independent interactions with human serum ensures a selective capture of therapeutic virus-specific CD8+ T-cells by multimer technology in Adoptive Immunotherapy.

Beloki L, Ciáurriz M, Mansilla C, Bandrés E, Rodríguez-Calvillo M, Ramírez N, Olavarría E.

J Immunol Methods. 2013 Oct 31;396(1-2):168-72. doi: 10.1016/j.jim.2013.07.014. Epub 2013 Aug 6.

PMID:
23933324
42.

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF.

N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439.

43.

Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective review.

Zabalza A, Gorosquieta A, Equiza EP, Olavarria E.

Ther Adv Hematol. 2013 Jun;4(3):217-30. doi: 10.1177/2040620713481796.

44.

Optic neuritis preceding progressive outer retinal necrosis in an immunocompromised patient after allogeneic stem cell transplantation.

Patel A, Olavarria E.

Ann Hematol. 2013 Oct;92(10):1427-9. doi: 10.1007/s00277-013-1699-z. Epub 2013 Feb 13. No abstract available.

PMID:
23404584
45.

Viral-specific adoptive immunotherapy after allo-SCT: the role of multimer-based selection strategies.

Ramírez N, Olavarría E.

Bone Marrow Transplant. 2013 Oct;48(10):1265-70. doi: 10.1038/bmt.2012.262. Epub 2013 Jan 14. Review.

PMID:
23318538
46.

Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation.

Basak GW, de Wreede LC, van Biezen A, Wiktor-Jedrzejczak W, Halaburda K, Schmid C, Schaap N, Dazzi F, von dem Borne PA, Petersen E, Beelen D, Abayomi A, Volin L, Buzyn A, Gurman G, Bunjes D, Guglielmi C, Olavarria E, de Witte T.

Bone Marrow Transplant. 2013 Jun;48(6):837-42. doi: 10.1038/bmt.2012.234. Epub 2012 Nov 26.

PMID:
23178548
47.

[Modern times: back to past, back to future].

Feliu J, Zabalza A, García-Muñoz R, Olavarría E.

Med Clin (Barc). 2012 Jul 7;139(4):180-1. doi: 10.1016/j.medcli.2011.11.029. Epub 2012 Jan 26. Spanish. No abstract available.

PMID:
22281094
48.

Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J.

Blood. 2011 Nov 17;118(20):5697-700. doi: 10.1182/blood-2011-07-367326. Epub 2011 Sep 16.

49.

Sign of the Zodiac as a predictor of survival for recipients of an allogeneic stem cell transplant for chronic myeloid leukaemia (CML): an artificial association.

Szydlo RM, Gabriel I, Olavarria E, Apperley J.

Transplant Proc. 2010 Oct;42(8):3312-5. doi: 10.1016/j.transproceed.2010.07.036.

PMID:
20970679
50.

Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarría E, Schmitz N, Sureda A.

J Clin Oncol. 2010 Oct 10;28(29):4492-9. doi: 10.1200/JCO.2010.29.3241. Epub 2010 Aug 9.

PMID:
20697072

Supplemental Content

Loading ...
Support Center